InvestorsHub Logo
Followers 18
Posts 1015
Boards Moderated 0
Alias Born 02/13/2013

Re: None

Thursday, 08/18/2016 1:49:48 AM

Thursday, August 18, 2016 1:49:48 AM

Post# of 733
Quote from the newsletter august 2016


"In our recent experiences most insurers, governmental and advisory bodies are coming to understand and accept the novel approach required to rank EPP amongst a new class of treatable diseases."

"Initially some of the national insurers were sceptical about the treatment value. Indeed, some suspected that each country would be paying more than its neighbour. As we progress, however, there is growing recognition of the transparent, fair approach Clinuvel has followed. A fixed price across the EU implies that Clinuvel is bearing the currency fluctuation in an economic zone where eleven different currencies prevail next to the Euro currency.
Each quarter we will report on the European progress in EPP. We expect seasonal influences due to the highest medical need expected from February to November. We receive clinical feedback that some countries require the treatment all year round, while others expect drug administration at times of highest light intensity and therefore increased risk of anaphylactoid reactions and burns.
Once the uniform pricing is introduced in the countries of reference and the majority of centres are actually dispensing the drug, Clinuvel will make the outcome of ongoing negotiations on pricing and reimbursement available. Our expectations and targets are being met, and for now we are reasonably content with the response we obtain from most national agencies and payors".